Leamington and Nuuvera any thoughts on the green linesPrincipal Purposes Upon the completion of the Nuuvera Private Placement and the Amalgamation, the Resulting Issuer will use the funds available to it to further its business objectives, which include (i) the purchase of land in Leamington from Aphria, (ii) construction of Avanti Site B in Canada, outside of Ontario, (iii) furthering its international business development, including construction of a GMP laboratory in Israel, acquisition of a GMP laboratory in Italy and the acquisition and upgrade of a laboratory facility in Malta, (iv) construction of the Avanti cultivation facility in Brampton, (v) the accumulation of inventory through the purchase of cannabis under the Supply Agreement and from international sources, (vi) non-capital costs to develop plans and obtain permits for the construction of the Leamington Facility, and (vii) general working capital purposes. As restrictions may prevent the Resulting Issuer from obtaining significant debt financing, management plans to maintain large cash balances to ensure Nuuvera can act quickly in a competitive market with respect to opportunities as they develop in the domestic and global markets. Specifically, management currently intends to use funds available over the next 12 months for the following purposes and in the following order of priority: Purchase land in Leamington $3,900,000 Construction of Avanti Site B $3,000,000 International business development $5,000,000 Construction of Avalon facility in Brampton $2,500,000 - 18 - Accumulation of cannabis inventory $7,600,000 Soft costs for development of Leamington Facility $2,000,000 General working capital $21,000,000 $45,000,000 See “Part III – Information Concerning Nuuvera” and “Part V – Information Concerning the Resulting Issuer”